ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: L16

Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Abstract Number: L17

Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Abstract Number: PP01

Why Communication Is the Most Important Thing in Healthcare
Abstract Number: PP02

Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
Abstract Number: PP03

To Err Is Human: The Need for Patients with Rheumatic and Musculoskeletal Diseases to Continuously Monitor Their Health Care Records
Abstract Number: PP04

Invisible to Invincible: The Role of Virtual Events in Autoimmune Advocacy, Education and Community Building
Abstract Number: PP05

From Practical Tips to Heartfelt Encouragement: How Social Media Can Improve Quality of Life with Rheumatic Disease
Abstract Number: PP06

Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
Abstract Number: PP07

Remissions and Vigilance
Abstract Number: PP08

Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Abstract Number: PP09

A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
Abstract Number: PP10

How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Abstract Number: PP11

Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Abstract Number: PP12

We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Abstract Number: PP13

How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].